Controller medications, also known as daily maintenance medications, are a critical tool for managing asthma — reducing daily ...

GSK's head of respiratory and immunology R&D, Kaivan Khavandi, said that the drug had achieved the "fundamental treatment goal in asthma" by slashing asthma attacks and hospitalisations.

It is one of GSK's top drugs, with sales of $2.2 billion last ... "Today's data, along with recent phase III data in severe asthma, will be used in regulatory filings around the world." ...

[1] All of these pathophysiologic features are largely represented in asthma, and therefore, anticholinergic drugs have been ... Chiesi, GlaxoSmithKline, MSD, Menarini, Novartis and Nycomed.

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

Understanding RSV: a significant threat for older adults this flu season ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.72B ...

its use is restricted within the allergic asthma subtype. The treatment of an already established exacerbation is more straight forward than its prevention. It comprises of oxygenation ...